You are an elite MBBS pharmacology professor, clinical pharmacologist, medical educator, pathophysiologist, and examination coach. Create a COMPLETE LEARNING NOTE for the topic(s) provided. The goal is NOT merely to summarize information. The goal is to teach the topic from absolute beginner level to MBBS examination mastery level. Assume the student has never seen the topic before. Write in extremely clear, plain English. Use language simple enough for a 9-year-old child to understand initially, then gradually build to MBBS level understanding. Never sacrifice understanding for brevity. Do not use unexplained jargon. Whenever a technical term is introduced: 1. Define it. 2. Explain why it matters. 3. Explain it using a simple analogy. 4. Explain it again in proper medical language. For every topic, use the following structure. --- SECTION 1: BIG PICTURE OVERVIEW Start with: "What problem does this drug class solve?" Explain: Why the disease occurs Why the microorganism survives What the drug is trying to achieve Where the drug acts Create a mental picture before discussing drugs. --- SECTION 2: BUILD THE FOUNDATION Before discussing drugs: Explain all background physiology. Explain all background microbiology. Explain all relevant pathology. Answer: What is normally happening? What goes wrong? Why does it go wrong? Where can drugs intervene? Use diagrams in text format where appropriate. Example: Bacterium ↓ Needs cell wall ↓ Cell wall keeps bacterium alive ↓ Drug blocks wall formation ↓ Wall becomes weak ↓ Bacterium dies --- SECTION 3: DRUG CLASS FRAMEWORK For each drug class explain: Definition Mechanism of action Why the mechanism works Spectrum of activity Important examples Clinical uses Adverse effects Contraindications Drug interactions Resistance mechanisms High-yield examination facts Common MCQs Most frequently tested concepts --- SECTION 4: TEACH USING ANALOGIES Create memorable analogies. Examples: Penicillin: "The bacterial cell wall is like a brick wall protecting a house. Penicillin prevents the workers from laying the bricks." Aminoglycosides: "The bacterial ribosome is like a factory producing products. Aminoglycosides force the factory to produce defective products." Sulfonamides: "Like cutting off a city's food supply." Always use vivid memorable analogies. --- SECTION 5: STEP-BY-STEP CLINICAL REASONING Teach how a doctor thinks. Example: Patient has pneumonia. Question 1: What organisms commonly cause it? Question 2: Which drugs cover those organisms? Question 3: Which drug reaches the lungs well? Question 4: What patient factors influence choice? Question 5: What adverse effects must be considered? Walk through reasoning systematically. --- SECTION 6: MEMORY TOOLS Create: Mnemonics Memory stories Visual memory tricks Drug comparison tables Rapid review boxes Focus only on useful mnemonics. --- SECTION 7: EXAMINER'S CORNER For each topic include: Most tested facts Most likely essay questions Most likely short notes Most likely viva questions Most likely MCQs Common traps students fall into How examiners phrase questions - SECTION 9: HIGH-YIELD REVISION SHEET End with: One-page revision summary Most important facts Must-know drugs Must-know toxicities Must-know mechanisms Must-know clinical uses Exam emergency facts --- SECTION 10: SELF-ASSESSMENT Create: 10 short-answer questions Provide answers with explanations. --- SPECIAL INSTRUCTIONS Do not assume prior knowledge. Teach before summarizing. Explain every mechanism step-by-step. Explain every adverse effect by linking it to physiology and pathophysiology. When discussing drugs, always answer: "What exactly is the drug doing?" "Why does that action help the patient?" "Why does that action produce the side effects?" "Why might resistance develop?" Use tables wherever helpful. Use comparison tables extensively. Make the note so comprehensive that an MBBS student can use it as their primary learning resource without needing another source for conceptual understanding. TOPICS TO COVER: Antidepressants

Reading File

Finding Sources

Searching PubMed

"antidepressants" AND "mechanism" AND "clinical use"

Good - I have key sources. Now let me read the most important ones in parallel.

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

I now have comprehensive data from the medical library. Let me update the todos and write the complete learning note.Now I'll write the comprehensive learning note:

COMPLETE LEARNING NOTE: ANTIDEPRESSANTS

From Absolute Beginner to MBBS Examination Mastery

SECTION 1: BIG PICTURE OVERVIEW

What Problem Does This Drug Class Solve?

Imagine your brain as a city. In this city, billions of tiny workers (called neurons - nerve cells) are constantly talking to each other by throwing chemical "messages" across tiny gaps. These chemical messages are called neurotransmitters (neuro = nerve, transmitter = something that sends a signal). The gap they cross is called the synapse (think of it as the space between two people talking to each other).

Now imagine that in some people, these chemical messages become too few, or the "receiving stations" that catch these messages stop working properly. When this happens in certain parts of the brain - especially the parts that control mood, motivation, sleep, appetite, and pleasure - the person begins to feel crushing sadness, loses interest in everything they once enjoyed, feels worthless, cannot sleep, cannot eat, cannot concentrate, and in severe cases, may want to die.

This is depression - or more precisely, Major Depressive Disorder (MDD).

The three most important chemical messengers involved are:

Serotonin - the "feel-good/calm" chemical. Controls mood, sleep, appetite, sexual function.
Norepinephrine (also called noradrenaline) - the "energy/drive" chemical. Controls alertness, concentration, motivation.
Dopamine - the "reward/pleasure" chemical. Controls motivation, pleasure, and reward.

The problem in depression (simplified): Not enough of these three chemicals are working properly at the right places in the brain.

What antidepressants do: They use different tricks to increase the activity of serotonin, norepinephrine, and/or dopamine at the synapse.

The key insight: The drugs work almost immediately on the chemistry, but the patient does not feel better for 2-4 weeks. This tells us the drugs are not simply "adding" the missing chemical - they are triggering slow structural and molecular changes inside the neurons themselves (including growth of new synaptic connections via BDNF - Brain-Derived Neurotrophic Factor). This is one of the most important and frequently tested facts about antidepressants.

SECTION 2: BUILD THE FOUNDATION

2A. Normal Brain Chemistry - What Is Normally Happening?

Step 1: The Neuron and the Synapse

A neuron is a nerve cell. Picture it like a long wire with a "body" (soma), a long tail (axon), and branching fingers at the end (dendrites). Neurons do not actually touch each other. There is always a microscopic gap between them - the synapse (or synaptic cleft).

PRESYNAPTIC NEURON        SYNAPSE         POSTSYNAPTIC NEURON
(the sender)             (the gap)         (the receiver)

[Axon terminal] ----[gap of ~20nm]---- [Dendrite/receptor]

Step 2: How a Chemical Message Is Sent

The presynaptic neuron makes neurotransmitters and stores them in small bags called vesicles.
An electrical signal travels down the axon.
The vesicles fuse with the cell membrane and release the neurotransmitter into the synapse.
The neurotransmitter floats across the gap and binds to receptors on the postsynaptic neuron.
This binding causes the postsynaptic neuron to either fire (get excited) or become quieter (get inhibited), depending on the receptor type.
To end the signal, the neurotransmitter is either:
- Taken back up into the presynaptic neuron (this is called reuptake) - this is the most important mechanism for serotonin and norepinephrine.
- Broken down by an enzyme called Monoamine Oxidase (MAO) inside the cell.

Presynaptic neuron makes serotonin
        ↓
Serotonin released into synapse
        ↓
Serotonin binds postsynaptic 5-HT receptors → signal sent → good mood
        ↓
Serotonin transporter (SERT) pumps serotonin BACK into presynaptic neuron
        ↓
MAO enzyme breaks down serotonin inside the neuron
        ↓
Signal ends

The reuptake transporter is the main target of most antidepressants. If you block the transporter, the neurotransmitter cannot be sucked back in, so it stays in the synapse longer, keeps hitting the receptor, and the signal is amplified.

Step 3: The Three Key Monoamines and Their Roles

Neurotransmitter	Abbreviation	Main Roles	Where Made in Brain
Serotonin	5-HT (5-hydroxytryptamine)	Mood, sleep, appetite, sexual function, gut motility	Raphe nuclei (brainstem)
Norepinephrine	NE / NA	Alertness, energy, concentration, stress response	Locus coeruleus (brainstem)
Dopamine	DA	Pleasure, motivation, reward, movement	Ventral tegmental area, Substantia nigra

Step 4: Autoreceptors - The Brain's Volume Control

This is a concept many students miss and examiners love to test.

The presynaptic neuron has its own receptors called autoreceptors (auto = self). These act like a feedback thermostat. When too much neurotransmitter builds up in the synapse, the autoreceptor detects it and signals the neuron to "slow down - we're making too much." This reduces the release of more neurotransmitter.

The most important autoreceptors are:

α2-adrenergic autoreceptors on norepinephrine neurons: when activated, they reduce NE release.
5-HT1A autoreceptors on serotonin neurons: when activated, they reduce 5-HT release.

Why this matters for drugs: When an SSRI is first started, it blocks the reuptake of 5-HT. 5-HT builds up in the synapse. The 5-HT1A autoreceptor detects this excess and fires a "stop making so much serotonin" signal. So the initial effect is blunted. Over 2-4 weeks, the autoreceptors downregulate (reduce in number/sensitivity), the brake is released, and full serotonergic activity is restored. This is why antidepressants take weeks to work.

2B. The Pathophysiology of Depression - What Goes Wrong?

The Monoamine Hypothesis (The Classic Explanation)

In the 1950s-1960s, scientists noticed:

Reserpine (an old blood pressure drug) depleted monoamines and caused depression in up to 20% of patients.
Isoniazid (a tuberculosis drug) inhibited MAO, increased monoamines, and caused euphoria.
Imipramine (accidentally discovered) blocked monoamine reuptake and improved depression.

These observations led to the Monoamine Hypothesis: Depression is caused by a deficiency of monoamine neurotransmitter activity (especially serotonin, norepinephrine, and dopamine).

Normal monoamine levels → Normal mood
       ↓
Deficiency of 5-HT / NE / DA at synapses
       ↓
Depression (sadness, loss of interest, fatigue, sleep disturbance, appetite changes)

Important limitation: This is a simplified hypothesis. Direct evidence for monoamine deficiency in depression is inconsistent. The hypothesis does NOT fully explain why drugs take 2-4 weeks to work when monoamine levels rise within hours of the first dose.

The Receptor Downregulation Hypothesis (Why Drugs Take Weeks)

When antidepressants increase monoamines:

Phase 1 (hours): Monoamine levels rise immediately - but autoreceptors fire, blunting the effect.
Phase 2 (1-2 weeks): Autoreceptors begin to desensitize (downregulate).
Phase 3 (2-4 weeks): Postsynaptic receptors also downregulate, and intracellular signaling changes. This correlates with clinical improvement.

The Neuroplasticity / BDNF Hypothesis (Modern Understanding)

Chronic stress and depression are associated with:

Decreased BDNF (Brain-Derived Neurotrophic Factor - a growth protein that maintains neuronal health and synapse formation)
Loss of dendritic spines (the tiny projections that receive signals)
Even measurable shrinkage of the hippocampus (the memory and emotion center) on MRI

Antidepressants, over weeks, restore BDNF levels, promote synapse formation, and may reverse some of this neuronal atrophy. This is the best current explanation for the delayed onset of antidepressant action.

Stress / Genetic vulnerability / Inflammation
        ↓
↓ BDNF → Loss of synaptic connections → Hippocampal atrophy
        ↓
DEPRESSION
        ↓
Antidepressant started
        ↓
↑ Monoamines → Downstream signaling → ↑ BDNF (takes 2-4 weeks)
        ↓
Synaptic restoration → Clinical improvement

The HPA Axis in Depression

The HPA axis (Hypothalamus - Pituitary - Adrenal axis) is the body's stress system. In many depressed patients:

The HPA axis is hyperactive - cortisol levels are chronically elevated.
High cortisol is toxic to hippocampal neurons.
This contributes to the neuroplasticity damage described above.

This explains why many depressed patients have the classic "high cortisol" features: poor sleep (especially early morning waking), high blood pressure, and metabolic changes.

2C. Where Can Drugs Intervene?

SITES OF DRUG ACTION IN THE SYNAPSE:

1. Block REUPTAKE TRANSPORTER → SSRIs, SNRIs, TCAs
   (keeps monoamine in synapse longer)

2. Block MAO enzyme → MAOIs
   (prevents breakdown of monoamine inside neuron)

3. Block AUTORECEPTORS → Mirtazapine (α2 blocker)
   (removes the "brake" on neurotransmitter release)

4. Block postsynaptic 5-HT2 receptors → Trazodone, Nefazodone
   (enhances other serotonin receptor subtypes)

5. Block NMDA receptors → Ketamine, Esketamine
   (rapid glutamate-based antidepressant effect)

6. Modulate GABA-A receptors → Brexanolone
   (used specifically in postpartum depression)

SECTION 3: DRUG CLASS FRAMEWORK

CLASS 1: SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)

Definition

SSRIs are drugs that selectively block the serotonin transporter (SERT), preventing the reuptake of serotonin from the synapse back into the presynaptic neuron. The result: serotonin accumulates in the synapse and acts for longer on the postsynaptic receptors.

The word "selective" means they primarily target serotonin and have minimal effects on norepinephrine, dopamine, histamine, or acetylcholine receptors - which is why they have far fewer side effects than the older antidepressants.

Drugs in This Class (Learn with "FESCPS"):

F - Fluoxetine (Prozac) - the prototype and oldest SSRI
E - Escitalopram (the most selective SSRI)
S - Sertraline (most commonly used worldwide)
C - Citalopram
P - Paroxetine
F - Fluvoxamine (mainly used for OCD)

Mechanism of Action (Step-by-Step)

Step 1: Normally, SERT pumps serotonin back into the presynaptic neuron after release
Step 2: SSRI binds to SERT and BLOCKS it
Step 3: Serotonin cannot be sucked back in
Step 4: Serotonin stays in the synapse
Step 5: Serotonin keeps hitting postsynaptic 5-HT receptors
Step 6: Enhanced serotonergic signaling
Step 7: Over 2-4 weeks → downregulation of autoreceptors + upregulation of BDNF
Step 8: Clinical antidepressant effect achieved

Pharmacokinetics (Key Facts)

Drug	Half-life	Active Metabolite	CYP Enzyme Effect	Special Feature
Fluoxetine	1-4 days (fluoxetine) + 4-16 days (norfluoxetine)	Norfluoxetine (active)	Potent CYP2D6 inhibitor	Longest half-life → least discontinuation syndrome; must wait 5 weeks before starting MAOI
Sertraline	~26 hours	Weak active metabolite	Modest CYP interaction	Safest in cardiac disease and pregnancy
Paroxetine	~21 hours	None	Potent CYP2D6 inhibitor	Worst discontinuation syndrome; most anticholinergic SSRI
Citalopram	~35 hours	None	Minimal CYP	Can prolong QT interval at high doses
Escitalopram	~27-32 hours	None	Minimal CYP	Most selective; fewest drug interactions; S-enantiomer of citalopram
Fluvoxamine	~15-20 hours	None	Potent CYP3A4 and CYP1A2 inhibitor	Mainly used for OCD; most CYP interactions

All SSRIs are well absorbed orally, highly protein bound, and metabolized in the liver.

Clinical Uses

Major Depressive Disorder (MDD) - FIRST LINE treatment
Generalized Anxiety Disorder (GAD)
Panic Disorder - all SSRIs
Obsessive-Compulsive Disorder (OCD) - fluvoxamine and sertraline especially; doses used are higher than for depression
Post-Traumatic Stress Disorder (PTSD) - sertraline and paroxetine are FDA approved
Social Anxiety Disorder - paroxetine and sertraline
Premenstrual Dysphoric Disorder (PMDD) - fluoxetine (brand: Sarafem)
Bulimia Nervosa - fluoxetine (only antidepressant FDA approved for bulimia)
Premature ejaculation - off-label (SSRIs delay orgasm)
Vasomotor symptoms of menopause - off-label

Adverse Effects (With Pathophysiology Explanations)

Adverse Effect	Why It Happens	Clinical Significance
GI effects (nausea, diarrhea, vomiting)	~95% of the body's serotonin is in the gut (enterochromaffin cells). Increasing 5-HT activity in the gut stimulates motility.	Most common early side effects. Usually resolve after 1-2 weeks. Take with food to minimize nausea.
Sexual dysfunction (decreased libido, delayed orgasm/ejaculation, anorgasmia)	5-HT2 receptor stimulation inhibits dopaminergic pathways that mediate sexual pleasure.	Very common (30-40% of patients). Often underreported. May require drug switch or addition of bupropion.
Insomnia / Agitation	5-HT2A receptor stimulation can cause arousal in some patients.	More common early in treatment. May improve with time. Paroxetine is more sedating due to its anticholinergic effect.
Weight gain	Complex mechanism; 5-HT2C receptor involvement; metabolic changes. Paroxetine causes most weight gain.	Paroxetine > other SSRIs for weight gain.
Hyponatremia (SIADH)	5-HT stimulates ADH (antidiuretic hormone) release from the posterior pituitary.	Important in elderly patients. Can cause confusion, seizures. Monitor serum sodium in at-risk patients.
Bleeding tendency	Serotonin is required for platelet aggregation (platelets use SERT for uptake). SSRIs deplete platelet serotonin, impairing aggregation.	Risk increased with NSAIDs or anticoagulants. Caution with patients on warfarin.
Discontinuation Syndrome	Abrupt stopping causes sudden fall in synaptic 5-HT due to rebound.	Features: FINISH mnemonic - Flu-like symptoms, Insomnia, Nausea, Imbalance, Sensory disturbances (electric shocks, "brain zaps"), Hyperarousal. Least with fluoxetine (long half-life). Worst with paroxetine.
QT prolongation	Citalopram/escitalopram block cardiac hERG channels at high doses.	Monitor ECG in patients on other QT-prolonging drugs. Dose limit: citalopram ≤40mg/day (≤20mg in elderly).

The Most Dangerous Adverse Effect: Serotonin Syndrome

Serotonin Syndrome is a potentially life-threatening condition caused by excess serotonin activity in the CNS and periphery.

Causes: Drug combinations that increase serotonin activity (SSRIs + MAOIs, SSRIs + tramadol, SSRIs + lithium, SSRIs + triptans, SSRIs + St. John's Wort)

Features - The Hunter Criteria Triad:

Neuromuscular hyperactivity: clonus (rhythmic involuntary muscle contractions), hyperreflexia, myoclonus, tremor, rigidity
Autonomic instability: hyperthermia, tachycardia, hypertension, diaphoresis, diarrhea
Altered mental status: agitation, delirium, confusion

The classic feature that distinguishes serotonin syndrome from NMS (neuroleptic malignant syndrome): CLONUS (especially inducible ocular clonus) and HYPERREFLEXIA (vs. lead-pipe rigidity in NMS).

Treatment: Stop all serotonergic drugs. Supportive care. Benzodiazepines for agitation. Cyproheptadine (5-HT antagonist) for severe cases.

Washout Period (CRITICAL for exams):

Before starting an MAOI, SSRIs must be stopped for:
- Fluoxetine: 5 weeks (due to long half-life of norfluoxetine)
- All other SSRIs: 2 weeks
Before starting an SSRI, an MAOI must be stopped for 2 weeks.

Important Drug Interactions

Interaction	Result	Example
SSRI + MAOI	Serotonin Syndrome (potentially fatal)	Fluoxetine + phenelzine
SSRI + Tramadol	Serotonin Syndrome	Sertraline + tramadol
SSRI + Triptans	Serotonin Syndrome (risk debated but real)	Fluoxetine + sumatriptan
Fluoxetine/Paroxetine + TCA	Increased TCA levels (CYP2D6 inhibition → TCA toxicity)	Fluoxetine + amitriptyline
SSRI + NSAIDs/Warfarin	Increased bleeding risk	Citalopram + aspirin
Fluvoxamine + Theophylline	Theophylline toxicity (CYP1A2 inhibition)
Fluvoxamine + Warfarin	Warfarin toxicity
SSRI + St John's Wort	Serotonin Syndrome

Contraindications

Concurrent MAOI use (serotonin syndrome)
Citalopram/escitalopram: congenital long QT syndrome
Paroxetine: pregnancy (especially first trimester - associated with cardiac defects; FDA category D)
SSRIs in general in pregnancy - PPHN (Persistent Pulmonary Hypertension of the Newborn) risk when used in 3rd trimester
Caution in bipolar disorder - can precipitate mania if used without a mood stabilizer

Suicidality Warning (Black Box)

The FDA mandated a Black Box Warning: SSRIs may increase suicidal ideation in children, adolescents, and young adults (under 25). The risk is greatest in the first 2 weeks. This is thought to be because the drug initially improves energy and motivation before fully lifting mood - a patient may gain the energy to act on suicidal thoughts before the thoughts themselves improve.

Despite this warning, the overall suicide rate in the population decreased as SSRI use increased - the untreated illness is more dangerous than the drug.

CLASS 2: SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs)

Definition

SNRIs block both the serotonin transporter (SERT) and the norepinephrine transporter (NET), thereby increasing both serotonin and norepinephrine in the synapse.

The added norepinephrine effect gives SNRIs advantages in:

Pain syndromes (norepinephrine pathways modulate pain in the descending spinal tracts)
Patients where SSRIs have failed
Patients with prominent fatigue or concentration problems

Drugs in This Class

Drug	SERT:NET Selectivity	Half-life	Special Feature
Venlafaxine	At low doses: mostly SERT inhibition. At higher doses: also NET inhibition.	8-11 hours (XR formulation allows once daily)	"Dose-dependent dual action" - SSRI-like at low dose, SNRI at higher dose
Desvenlafaxine	More balanced SERT/NET	8-11 hours	Active metabolite of venlafaxine; lowest protein binding of all antidepressants (27-30%)
Duloxetine	More balanced than venlafaxine	12-15 hours	FDA approved for diabetic neuropathy, fibromyalgia, stress urinary incontinence, chronic musculoskeletal pain
Milnacipran / Levomilnacipran	Greater NET selectivity (unusual among SNRIs)	Shorter	Levomilnacipran FDA approved for MDD; milnacipran approved for fibromyalgia in USA

Clinical Uses

MDD - same as SSRIs; often used when SSRIs fail
Generalized Anxiety Disorder (venlafaxine and duloxetine)
Diabetic peripheral neuropathy (duloxetine)
Fibromyalgia (duloxetine, milnacipran)
Chronic musculoskeletal pain (duloxetine)
Stress urinary incontinence (duloxetine - approved in Europe)
Migraine prevention (venlafaxine)
Menopausal vasomotor symptoms (venlafaxine)

Adverse Effects

Similar to SSRIs: GI upset, sexual dysfunction, insomnia
Added NE effects: hypertension (especially venlafaxine at high doses - norepinephrine → vasoconstriction), increased heart rate, increased sweating
Discontinuation syndrome (worse with venlafaxine than SSRIs due to short half-life)
Duloxetine: hepatotoxicity (rare but important; avoid in liver disease)
Venlafaxine: monitor blood pressure

CLASS 3: TRICYCLIC ANTIDEPRESSANTS (TCAs)

Definition

TCAs are older antidepressants with a three-ring (tricyclic) chemical structure. They block both SERT and NET (like SNRIs), but they also lack selectivity - they block many other receptors, causing a wide range of adverse effects.

Think of TCAs as the "original SNRIs" that come packaged with many undesirable extra actions.

Why "Tricyclic"?

The name comes from their chemical structure - three connected rings (like three linked wedding bands). This 3-ring structure gives them affinity for many different receptors.

Drugs in This Class

Tertiary Amines (more sedating, more anticholinergic, more side effects):

Amitriptyline
Imipramine (the first TCA, discovered 1957)
Clomipramine (most serotonin-selective TCA - drug of choice for OCD)
Doxepin (also used for insomnia and pruritus due to potent H1 blockade)
Trimipramine

Secondary Amines (metabolites of tertiary amines; fewer side effects):

Nortriptyline (metabolite of amitriptyline) - best tolerated TCA; therapeutic drug monitoring available
Desipramine (metabolite of imipramine) - most norepinephrine selective; least anticholinergic TCA

Memory tip: Desipramine → Desirable for NE | Clomipramine → Cleans OCD (serotonin)

Mechanism of Action - Multiple Receptor Blockades

Action	Receptor	Result
Block SERT	Serotonin transporter	Antidepressant, anti-OCD (clomipramine)
Block NET	Norepinephrine transporter	Antidepressant, analgesic
Block muscarinic receptors (M1)	Anticholinergic effect	Dry mouth, constipation, urinary retention, blurred vision, tachycardia, confusion in elderly
Block histamine H1 receptors	Antihistamine effect	Sedation, weight gain
Block alpha-1 adrenergic receptors	Alpha blockade	Orthostatic hypotension
Block cardiac sodium channels	Quinidine-like cardiac effect	QRS prolongation, arrhythmias (DANGEROUS IN OVERDOSE)

Clinical Uses

Depression (less preferred now due to side effects, but still useful)
OCD - clomipramine (drug of choice when SSRI fails)
Neuropathic pain / Diabetic neuropathy - amitriptyline
Migraine prophylaxis - amitriptyline (mechanism: independent of antidepressant action, often at lower doses)
Enuresis (bedwetting) in children - imipramine (though less commonly used now)
Fibromyalgia / Chronic pain - amitriptyline
Panic disorder - imipramine
Insomnia - doxepin (low dose)
Pruritus - doxepin cream (H1 blockade)

Adverse Effects (The "4 A's" of TCA toxicity)

Anti-muscarinic (Anticholinergic) effects:

Dry mouth (xerostomia)
Blurred vision (cycloplegia)
Constipation
Urinary retention (especially in men with benign prostatic hypertrophy - BPH)
Tachycardia
Memory impairment / confusion (especially in elderly)
Contraindicated in narrow-angle glaucoma (pupil dilation by anticholinergic effect increases intraocular pressure)

Anti-adrenergic (α1 blockade) effects:

Orthostatic hypotension (most common cause of falls in elderly on TCAs)
Dizziness, syncope
Reflex tachycardia

Antihistamine effects:

Sedation
Weight gain

Cardiac toxicity (The most dangerous TCA effect - especially in overdose):

TCAs block cardiac fast sodium channels (like quinidine)
Result: Widening of QRS complex on ECG → conduction block → ventricular arrhythmias
In overdose: "3 C's" - CNS depression, Convulsions, Cardiac arrhythmias
TCAs are the most lethal antidepressant in overdose
Specific ECG finding: QRS > 100ms predicts arrhythmias; QRS > 160ms predicts ventricular fibrillation
Treatment of TCA overdose: Sodium bicarbonate (IV) - alkalinizes blood → reduces TCA-Na channel binding; reduces free drug; increases protein binding

Contraindications

Recent myocardial infarction
Narrow-angle glaucoma
Benign prostatic hypertrophy (relative contraindication)
Cardiac arrhythmias / heart block
Elderly patients (high risk of falls, confusion, urinary retention)
With MAOIs (serotonin syndrome risk)

The "dirty dozen" of TCA side effects can be remembered as everything you get when acetylcholine is blocked (dry, blind, constipated, can't urinate, fast heart) + adrenergic blockade (dizzy when standing) + histamine blockade (sleepy, fat).

CLASS 4: MONOAMINE OXIDASE INHIBITORS (MAOIs)

Background

The enzyme Monoamine Oxidase (MAO) is found inside neurons and on the outer surface of mitochondria. It breaks down monoamine neurotransmitters (serotonin, norepinephrine, dopamine) INSIDE the neuron after reuptake. There are two forms:

MAO-A: Metabolizes norepinephrine, serotonin, and dopamine. Located in brain, gut, placenta, liver.
MAO-B: Metabolizes dopamine, tyramine, phenylethylamine. Located in brain, liver, platelets.

Drugs in This Class

Drug	Type	Selectivity	Reversibility	Notes
Phenelzine	Classic antidepressant MAOI	Non-selective (A+B)	Irreversible	Risk of tyramine reaction; most anxiolytic MAOI
Tranylcypromine	Classic antidepressant MAOI	Non-selective (A+B)	Irreversible	Also has some amphetamine-like stimulant effects
Isocarboxazid	Classic antidepressant MAOI	Non-selective (A+B)	Irreversible	Less commonly used
Selegiline	Parkinson's drug (low dose) / antidepressant (high dose)	Selective MAO-B at low dose; non-selective at high dose	Irreversible	Patch formulation (Emsam) for depression - less tyramine risk; low dose used for Parkinson's
Moclobemide	Antidepressant (not available in USA)	Selective MAO-A	Reversible (RIMA)	Less tyramine interaction risk because tyramine can DISPLACE it

Mechanism

MAOIs inhibit the MAO enzyme → neurotransmitters are not broken down inside the neuron → more available for release → enhanced monoaminergic transmission.

Because MAO also metabolizes tyramine in the gut and liver, MAOI use creates dangerous accumulation of tyramine if tyramine-rich foods are eaten.

The Tyramine (Cheese) Reaction - THE MOST IMPORTANT MAOI FACT

Tyramine is a naturally occurring amine found in fermented and aged foods. Normally, MAO-A in the gut wall and liver metabolizes any tyramine absorbed from food before it reaches the systemic circulation (a "first-pass" protection mechanism).

When MAO is inhibited:

Tyramine escapes this first-pass metabolism
Tyramine reaches systemic circulation
Tyramine enters adrenergic nerve terminals and causes a massive release of norepinephrine and other catecholamines
This causes sudden, severe hypertension (hypertensive crisis)

Clinical features: Sudden severe headache (often described as "worst headache of life"), palpitations, sweating, facial flushing, hypertension, risk of hypertensive encephalopathy, stroke, or intracranial hemorrhage.

Foods to AVOID on MAOIs (Tyramine-rich foods):

Category	Examples
Aged/fermented cheeses	Cheddar, Brie, Camembert, blue cheese
Cured/smoked meats	Salami, pepperoni, aged sausage
Fermented foods	Sauerkraut, kimchi, miso
Alcoholic beverages	Beer (especially draft/craft), wine, chianti
Broad/fava beans	Contain dopamine precursors
Yeast extracts	Marmite, Vegemite
Fermented soy products	Soy sauce, tofu (some types)
Overripe/aged fruits	Overripe bananas, avocados, figs

The classic exam question: "A patient on phenelzine ate a cheese sandwich and developed sudden severe headache and blood pressure of 220/130 mmHg. What happened?" Answer: Tyramine hypertensive crisis.

Clinical Uses of MAOIs

Treatment-resistant depression (when SSRIs, SNRIs, and TCAs have failed)
Atypical depression (depression with mood reactivity, hypersomnia, weight gain, rejection hypersensitivity, leaden paralysis) - MAOIs are MORE effective than TCAs for this subtype
Panic disorder (phenelzine)
Social phobia
Selegiline (low dose): Parkinson's disease (neuroprotection hypothesis)

Drug Interactions with MAOIs (All Potentially Life-Threatening)

Interacting Drug	Mechanism	Result
SSRIs	Both increase serotonin → excess 5-HT	Serotonin syndrome
TCAs	Both increase NE + 5-HT	Serotonin syndrome + hypertension
Meperidine (pethidine)	Mechanism unclear - possibly 5-HT release	Serotonin syndrome (specific to pethidine - other opioids have lower risk)
Tramadol	Weak SERT inhibitor + opioid	Serotonin syndrome
Triptans (sumatriptan)	Both increase 5-HT activity	Serotonin syndrome
Sympathomimetics (ephedrine, pseudoephedrine)	Release of NE	Hypertensive crisis
Levodopa	Increased dopamine → MAO converts excess to NE	Hypertension
Tyramine (food)	See above	Hypertensive crisis

CLASS 5: ATYPICAL / NEWER ANTIDEPRESSANTS

5A. Mirtazapine (NaSSA - Noradrenergic and Specific Serotonergic Antidepressant)

Mechanism (The Most Unique in This Class):

Mirtazapine does NOT block any reuptake transporter. Instead, it works by:

Blocking α2-adrenergic autoreceptors (presynaptic) on BOTH norepinephrine AND serotonin neurons. Normally, these autoreceptors act as a brake - when activated, they reduce neurotransmitter release. By blocking these brakes, mirtazapine causes INCREASED release of both NE and 5-HT.
Blocking 5-HT2A, 5-HT2C, and 5-HT3 receptors (postsynaptic). This makes serotonin "use" the 5-HT1A receptor (the "good" receptor for antidepressant effects) while avoiding the side-effect receptors.
Potent H1 histamine blockade: causes sedation and weight gain.

Result: Increased 5-HT and NE activity, but without the sexual dysfunction and GI side effects seen with SSRIs/SNRIs (because the 5-HT2 and 5-HT3 receptors that mediate these are blocked).

Clinical Advantages:

Useful when sexual dysfunction is a concern
The potent sedation and appetite stimulation are useful in depressed patients with insomnia and weight loss
No sexual dysfunction (a major advantage)
Fast onset of sedation (H1 blockade starts immediately)
Paradox: The sedation is LESS pronounced at higher doses - because at higher doses, NE stimulation counteracts the H1-mediated sedation.

Adverse Effects:

Sedation (very common)
Weight gain (significant - among the worst for weight gain)
Dry mouth
Increased appetite
Minimal sexual dysfunction
Agranulocytosis (rare but important - monitor WBC)

5B. Bupropion (Wellbutrin, Zyban)

Mechanism:

Inhibits norepinephrine and dopamine reuptake (NDRI: Norepinephrine-Dopamine Reuptake Inhibitor)
Also promotes presynaptic release of catecholamines
Virtually no effect on serotonin

Clinical Uses:

MDD - especially when SSRIs cause sexual dysfunction or fatigue
Smoking cessation (Zyban) - reduces nicotine craving via dopamine and NE pathways
ADHD (off-label)
Obesity (in combination with naltrexone - brand: Contrave)
Sexual dysfunction caused by other antidepressants

Key Adverse Effects:

Seizures (the most important) - dose-dependent risk. Contraindicated in patients with seizure disorders, history of eating disorders (electrolyte abnormalities from purging lower seizure threshold), or head trauma. Do NOT exceed 450mg/day or individual doses > 150mg (IR) / 200mg (XL) due to seizure risk.
Insomnia and agitation (NE/DA activation)
No sexual dysfunction (unique advantage - no serotonin effect)
No weight gain (often causes mild weight loss)
Can lower blood pressure slightly
Dry mouth, headache

Contraindications:

Seizure disorder
Eating disorders (anorexia, bulimia) - due to seizure risk
Abrupt discontinuation of alcohol or benzodiazepines (lower seizure threshold)

5C. Trazodone

Mechanism:

Weak SERT inhibitor
Potent 5-HT2A receptor antagonist (main antidepressant mechanism)
Weak α1-adrenergic blocker

Clinical Uses:

Insomnia (most common current use - at low doses 50-100mg)
Depression (at higher doses - 300-600mg)
Agitation in dementia

Key Adverse Effects:

Priapism (prolonged, painful penile erection - rare but urological emergency requiring treatment within 4-6 hours to prevent permanent erectile dysfunction). Mechanism: α1 blockade leads to vasodilation in penile tissue.
Orthostatic hypotension (α1 blockade)
Sedation (H1 + 5-HT2 blockade)
Relatively safe in overdose compared to TCAs

Memory: "Trazo-DONE - it's done with erections" (priapism risk)

5D. Nefazodone

Similar to trazodone in mechanism
Potent CYP3A4 inhibitor - many drug interactions
Hepatotoxicity (rare but serious - including liver failure; significantly restricts its use)

5E. Vortioxetine (Brintellix)

Mechanism: Multimodal serotonin modulator:

Inhibits SERT
Partial agonist at 5-HT1A receptors
Antagonist at 5-HT1D, 5-HT3, 5-HT7 receptors
May improve cognitive function (a proposed advantage over other antidepressants)

Uses: MDD, especially when cognitive symptoms are prominent

5F. Agomelatine (not available in USA)

Melatonin receptor agonist (MT1 and MT2) + 5-HT2C antagonist
Unique: resynchronizes circadian rhythms
Improves sleep architecture
Hepatotoxic (monitor liver function)

CLASS 6: KETAMINE AND ESKETAMINE (NMDA Receptor Antagonists)

This represents a paradigm shift in antidepressant treatment.

Background

Traditional antidepressants take 2-4 weeks. In severe depression with suicidal ideation, this delay is dangerous. Ketamine produces antidepressant effects within hours to days.

Mechanism

Non-competitive NMDA (N-methyl-D-aspartate) receptor antagonist - blocks glutamate's action
NMDA receptors are involved in synaptic plasticity and neural circuits for depression
Blocking NMDA receptors rapidly increases BDNF and promotes synaptogenesis
Additional mechanisms: opioid receptor interaction, monoaminergic effects

Drugs

Ketamine (IV infusion - off-label)
Esketamine (Spravato) - S-enantiomer of ketamine; FDA approved (2019) as intranasal spray for treatment-resistant depression and MDD with acute suicidal ideation

Uses

Treatment-resistant depression (when 2+ adequate antidepressant trials have failed)
MDD with acute suicidal ideation (esketamine)
Bipolar depression (some evidence)

Adverse Effects

Dissociation (feeling of unreality, detachment) - dose-dependent; during infusion
Psychomimetic effects (hallucinations, perceptual disturbances)
Nausea
Dizziness
Hypertension (transient, during infusion)
Potential for abuse and dependence
Esketamine requires REMS (Risk Evaluation and Mitigation Strategy) program - administered only in certified healthcare settings under observation

CLASS 7: BREXANOLONE (ZULRESSO)

First FDA-approved drug specifically for postpartum depression (2019)
Mechanism: Positive allosteric modulator of GABA-A receptors (both synaptic and extrasynaptic)
It is a synthetic form of allopregnanolone (a neuroactive steroid - metabolite of progesterone)
In postpartum depression, there is a sudden drop in neuroactive steroids after delivery; brexanolone replaces this
Given as a single 60-hour IV infusion - produces antidepressant effects that can last weeks
Very expensive; requires a monitored clinical setting (REMS program)
Oral version in development: Zuranolone

SECTION 4: TEACH USING ANALOGIES

SSRIs - "The River Dam Analogy"

Imagine serotonin is water flowing through a river. The synapse is a pool between two cliffs. Normally, after the water fills the pool (signal sent), a drain opens at the bottom and quickly removes the water (reuptake). The pool empties fast, and the water level never gets high.

An SSRI is like plugging the drain. The water cannot drain away. The pool level rises. The water stays for much longer, doing its job. The postsynaptic receptors (fish living at the bottom of the pool) are continuously bathed in serotonin.

But here's the twist: there's also a small pipe from the pool back to the source - the autoreceptor. When the pool gets too full, a valve at the source closes (autoreceptor activation). So initially, the source reduces its output. Over weeks, the valve mechanism breaks down (autoreceptor downregulation), the source stays fully open, and you truly have a flooded pool. That's why it takes weeks.

TCAs - "The Security Guard Who Arrests Everyone"

Think of SERT and NET as "wanted criminals." A TCA is like a security guard who is supposed to arrest only these two criminals. But this security guard is not well-trained. In his enthusiasm, he also arrests:

The hotel concierge (muscarinic receptors) → hotel services stop: dry mouth, constipation, urinary retention, blurred vision
The electricity maintenance man (cardiac Na+ channels) → electricity fails: arrhythmias
The night watchman (H1 receptor) → the building falls asleep: sedation
The traffic policeman (α1 receptors) → traffic chaos: orthostatic hypotension

"Selective" SSRIs are trained police dogs who catch only one specific criminal.

MAOIs - "The Garbage Disposal Analogy"

Imagine monoamines are dinner table scraps. After every meal (nerve firing), these scraps need to be disposed of - MAO is the kitchen garbage disposal. It grinds up the used monoamines inside the neuron.

An MAOI breaks the garbage disposal. Scraps pile up. There are now MORE monoamines available for the next meal. The table overflows with food (monoamines) at every meal.

The problem: MAO in the gut was also grinding up tyramine from food - acting like a bouncer at the door. With MAO inhibited, tyramine crashes into the blood system, reaches the neurons, and triggers a massive adrenaline storm. That's the tyramine hypertensive crisis.

Mirtazapine - "The Brake-Releasing Analogy"

Imagine serotonin and norepinephrine neurons as race cars on a track. They have accelerators (the nerve signals telling them to fire) but also brakes (the α2 autoreceptors). When the brakes are on, the cars go slowly, releasing little neurotransmitter.

Mirtazapine cuts the brake cables (blocks α2 receptors). The cars now run at full speed - releasing large amounts of 5-HT and NE. Additionally, mirtazapine blocks the rough roads (5-HT2, 5-HT3 receptors) so the passengers (patient) don't feel sick or sexually dysfunctional.

Bupropion - "The Dopamine Fuel Booster"

While SSRIs work on the mood (serotonin highway), bupropion works on the reward and motivation (dopamine-norepinephrine highway). Think of it as fuel injection for the dopamine engine.

Smokers trying to quit: nicotine normally keeps the dopamine engine running. Bupropion substitutes for nicotine's dopaminergic effects, making the transition less painful.

But too much fuel (too high a dose) causes the engine to backfire: seizures.

Ketamine - "The Fast Rerouting Analogy"

Classic antidepressants try to gradually rebuild a damaged neighborhood (the depressed brain circuits) brick by brick over weeks.

Ketamine is like calling in an emergency construction team that works overnight. It rapidly builds new scaffolding (synaptic connections via BDNF) around a completely different road (the glutamate-NMDA system, not just monoamines). By morning, the neighborhood is functional again. Within hours to days, the patient feels better. The effect may last weeks to months even after a single treatment.

SECTION 5: STEP-BY-STEP CLINICAL REASONING

Clinical Scenario 1: 32-year-old woman with major depression

Patient: 32F, 6 weeks of low mood, poor sleep, loss of interest, low appetite, inability to concentrate at work. No suicidal ideation. No prior psychiatric history. Healthy otherwise. No medications. Currently taking oral contraceptive pill (OCP).

Step 1: Confirm the diagnosis

DSM-5 criteria for MDD: ≥5 of 9 symptoms for ≥2 weeks, causing significant impairment. Must include depressed mood or anhedonia (loss of interest/pleasure).
Rule out: thyroid disease (TSH), anemia (CBC), bipolar disorder (past manic episodes?), substance use.

Step 2: Decide whether to treat with medication

Mild depression: psychotherapy alone (CBT) is as effective as medication
Moderate-severe depression: medication recommended, often in combination with CBT
This patient has 6-week duration with functional impairment → medication appropriate

Step 3: Which drug class?

FIRST LINE: SSRI or SNRI
MAOIs: third line (reserved for treatment-resistant)
TCAs: avoided due to side effect burden

Step 4: Which specific SSRI? Consider:

Sertraline or escitalopram: safest, fewest interactions, well-tolerated → preferred first choice
Paroxetine: avoid in this woman of childbearing age (teratogenic)
Fluoxetine: suitable but note OCP interaction minimal; long half-life beneficial
Fluvoxamine: more drug interactions; mainly used for OCD

Answer: Sertraline 50mg daily or Escitalopram 10mg daily

Step 5: How to start?

Start low, go slow (start 50mg sertraline or 10mg escitalopram)
Warn patient: GI side effects in first 2 weeks, possible initial anxiety/agitation
No clinical improvement expected for 2-4 weeks
Follow up at 2 weeks (suicidality check) and 6-8 weeks (treatment response assessment)
If partial response at 8 weeks: increase dose
If no response at 8-12 weeks: switch drug or add augmentation agent

Step 6: How long to treat?

Minimum 6-12 months after remission to reduce relapse risk
Two or more prior episodes: consider long-term maintenance therapy
Taper slowly when discontinuing (avoid discontinuation syndrome)

Clinical Scenario 2: 55-year-old man with depression + diabetic neuropathy

Why this matters: This patient has TWO problems that can be targeted simultaneously.

Duloxetine (SNRI) is FDA approved for BOTH MDD and diabetic peripheral neuropathy
One drug, two problems solved
Alternatively: Pregabalin or gabapentin for neuropathy alone, but if depression is also present, duloxetine is elegant

Clinical Scenario 3: Depressed patient on phenelzine presents to emergency with BP 230/140

Diagnosis: Tyramine hypertensive crisis (cheese reaction) due to MAOI What happened: Patient ate aged cheese / cured meat / drank beer Management:

IV antihypertensives: phentolamine (α-blocker) or nitroprusside
NOT beta-blockers alone (can paradoxically worsen hypertension by leaving α-receptors unopposed)
Monitor for stroke, MI

Clinical Scenario 4: Patient on SSRI + tramadol after dental surgery develops agitation, tachycardia, diaphoresis, hyperreflexia, and clonus

Diagnosis: Serotonin Syndrome Mechanism: Tramadol has weak SSRI-like properties + SSRI → excess serotonin Management:

Stop all serotonergic drugs
Benzodiazepines for agitation and temperature control
Cyproheptadine (5-HT antagonist) - oral; used in moderate cases
Supportive: cooling, IV fluids
ICU for severe cases (hyperthermia >41°C is life-threatening)

Clinical Scenario 5: Severely depressed patient with acute suicidal ideation, failed 3 antidepressants

Option: Esketamine (Spravato) intranasal + SSRI/SNRI

Esketamine FDA approved for treatment-resistant depression (TRD) and MDD with acute suicidal ideation
Works within hours to days
Given in monitored healthcare setting only
Patient must be observed for ≥2 hours after each dose

SECTION 6: MEMORY TOOLS

Mnemonic 1: SSRIs - "FESCPS" (or "FLAPS Cry")

Alternate: "Sad Feelings? Escape! Pause. Consider Fluoxetine."

Sertraline
Fluvoxamine
Escitalopram
Paroxetine
Citalopram
Fluoxetine

Mnemonic 2: Tyramine-containing foods (MAOI contraindicated foods)

"ACE A FISH BOARD"

Aged cheese
Cured meats (salami, pepperoni)
Excess fermented foods (kimchi, sauerkraut)
Alcohol (beer, wine)
Fava beans
Instant/chicken liver (organ meats - stored)
Smoked/pickled fish
High-tyramine soy sauce
Bananas (overripe)
Overdue/expired foods
Avocados (overripe)
Raisins
Dried fruits

Mnemonic 3: TCA Adverse Effects - "ABCDE"

Anticholinergic: dry mouth, constipation, urinary retention, blurred vision, tachycardia
Blood pressure drop (orthostatic hypotension via α1 blockade)
Cardiotoxicity (QRS widening, arrhythmias - quinidine-like Na+ channel block)
Drowsiness and weight gain (H1 blockade)
Endocrine: sexual dysfunction

Mnemonic 4: Serotonin Syndrome Features - "FLAMES"

Fever (hyperthermia)
Labile vitals (tachycardia, hypertension)
Agitation / Altered consciousness
Myoclonus / Muscle rigidity
Excitement (hyperreflexia, clonus)
Sweating (diaphoresis)

Mnemonic 5: SSRI Discontinuation Syndrome - "FINISH"

Flu-like symptoms
Insomnia
Nausea
Imbalance (dizziness)
Sensory disturbances ("brain zaps," electric-shock sensations)
Hyperarousal, irritability

Mnemonic 6: MAOIs - "Pit SIT"

Phenelzine
Isocarboxazid
Tranylcypromine
Selegiline (selective MAO-B)
Inhibit MAO
Tyramine reaction risk

Mnemonic 7: Drug of Choice for Special Situations

Situation	Drug of Choice	Memory Hook
Depression + OCD	Clomipramine (TCA) or Fluvoxamine (SSRI)	"Clomi-OCD-pramine"; "Fluvoxamine = Fluvo-OCD"
Depression + smoking cessation	Bupropion	"Bupropion busts smoking"
Depression + insomnia + weight loss	Mirtazapine	"Mirtazapine = More appetite, More sleep"
Depression + neuropathy + fibromyalgia	Duloxetine	"Duloxetine = Dual (depression + pain)"
Depression + sexual dysfunction (existing)	Bupropion	"Bupro = No sexual side effects"
Atypical depression	MAOIs > TCAs
Postpartum depression	Brexanolone	"Brex = Birth + RElax"
Treatment-resistant + suicidal	Esketamine	"Esketamine = Escape from TRD"
Depression + PTSD	Sertraline or Paroxetine	Both FDA-approved for PTSD
Bedwetting (enuresis) in children	Imipramine	"Imipramine = Improving bedtime"
Bulimia nervosa	Fluoxetine	"Fluoxetine fights binging"

Rapid Comparison Table: Major Antidepressant Classes

Feature	SSRIs	SNRIs	TCAs	MAOIs	Mirtazapine	Bupropion
Primary mechanism	Block SERT	Block SERT + NET	Block SERT + NET + multiple receptors	Inhibit MAO	Block α2, 5-HT2, H1	Block NET + DAT
Sexual dysfunction	Common	Common	Common	Common	Rare	Rare/absent
Weight gain	Mild	Mild	Significant	Variable	Significant	Weight loss
Sedation	Low-moderate	Low	High	Low-moderate	High	Stimulant
Cardiac safety	Safe	Safe (mild BP↑ with SNRI)	DANGEROUS (arrhythmias)	Moderate risk	Safe	Safe
Seizure risk	Low	Low	Moderate	Low	HIGH
Overdose danger	Low	Low	HIGH	Moderate	Low	Moderate
Drug interactions	Moderate (CYP)	Low-moderate	Moderate	EXTREME (MAOI)	Low	Low-moderate
Lethal with MAOI?	YES (serotonin syndrome)	YES	YES	-	Low risk	Low risk
First-line for MDD?	YES	YES	No (2nd line)	No (3rd line)	Alternative	Alternative

SECTION 7: EXAMINER'S CORNER

Most Tested Facts

Onset of action of antidepressants: 2-4 weeks - most frequently tested; know WHY (receptor downregulation, BDNF)
Fluoxetine washout before MAOI: 5 weeks (others: 2 weeks) - because of norfluoxetine half-life
Tricyclic overdose treatment: IV Sodium Bicarbonate - not just supportive care
Bupropion + seizures + eating disorders - contraindicated
Tyramine (cheese) reaction with MAOIs
Serotonin Syndrome: treatment = stop drugs + cyproheptadine (5-HT antagonist)
Clomipramine = TCA with most serotonin selectivity = best TCA for OCD
Fluoxetine for bulimia (FDA approved)
Mirtazapine: paradox - more sedation at lower doses
Paroxetine: avoid in pregnancy (FDA Cat D), worst discontinuation syndrome

Most Likely Essay Questions

"Classify antidepressants with their mechanism of action. Discuss the adverse effects of SSRIs."
"Describe the mechanism of action, clinical uses, and adverse effects of tricyclic antidepressants."
"What is serotonin syndrome? How does it occur, and how is it treated?"
"Describe the pharmacological management of major depressive disorder."
"What are MAO inhibitors? Discuss their interactions and the dietary restrictions required."

Most Likely Short Notes

Serotonin syndrome
Tyramine reaction with MAOIs
Bupropion (mechanism, uses, contraindications)
Mirtazapine (mechanism and advantages)
Drug of choice in different types of depression
Discontinuation syndrome
Fluoxetine - special pharmacokinetic features
Treatment-resistant depression

Most Likely Viva Questions

"Why does it take 2-4 weeks for antidepressants to work if they increase monoamines immediately?" (Answer: receptor downregulation, BDNF synthesis delay, autoreceptor desensitization)
"Why is sodium bicarbonate used in TCA overdose?" (Answer: alkalinization reduces drug-Na channel binding; shifts drug into protein-bound form; corrects QRS widening)
"Name an antidepressant that does not cause sexual dysfunction." (Bupropion, mirtazapine)
"Which SSRI is safest in cardiac disease?" (Sertraline)
"Which TCA would you choose for OCD and why?" (Clomipramine - most serotonin-selective TCA)
"Why should paroxetine not be used in pregnancy?" (Cardiac malformations in first trimester; PPHN risk in third trimester)

Most Likely MCQs

A patient on phenelzine eats aged cheddar cheese and develops severe headache with BP 230/140. This is due to:
- A) Serotonin syndrome
- B) Tyramine hypertensive crisis [CORRECT]
- C) Hypoglycemia
- D) Drug-drug interaction with cheese
The washout period required between fluoxetine and an MAOI is:
- A) 2 weeks
- B) 3 weeks
- C) 4 weeks
- D) 5 weeks [CORRECT] (due to long half-life of norfluoxetine)
An antidepressant with LEAST sexual dysfunction:
- A) Paroxetine
- B) Sertraline
- C) Bupropion [CORRECT]
- D) Venlafaxine
The drug of choice for OCD is:
- A) Amitriptyline
- B) Clomipramine (if SSRI fails) [CORRECT for TCA] / Fluoxetine/Sertraline [CORRECT for SSRIs, first line]
- C) Imipramine
- D) Mirtazapine
Sodium bicarbonate is the treatment of choice for overdose of:
- A) Fluoxetine
- B) Amitriptyline [CORRECT]
- C) Venlafaxine
- D) Bupropion
A 25-year-old woman on sertraline develops fever, diaphoresis, agitation, clonus, and hyperreflexia after adding tramadol for dental pain. Most likely diagnosis:
- A) Neuroleptic malignant syndrome
- B) Serotonin syndrome [CORRECT]
- C) Anticholinergic toxidrome
- D) Malignant hyperthermia
Which antidepressant is specifically indicated for postpartum depression?
- A) Fluoxetine
- B) Sertraline
- C) Brexanolone [CORRECT]
- D) Mirtazapine
Bupropion is contraindicated in:
- A) Parkinson's disease
- B) Bulimia nervosa [CORRECT - seizure risk]
- C) Hypertension
- D) Diabetes mellitus
The antidepressant with the LONGEST half-life is:
- A) Paroxetine
- B) Fluvoxamine
- C) Fluoxetine [CORRECT] (due to norfluoxetine metabolite: total ~5-7 weeks)
- D) Sertraline
A patient on a TCA overdose presents with QRS >120ms on ECG. The most important immediate treatment is:
- A) Activated charcoal
- B) IV Sodium Bicarbonate [CORRECT]
- C) Physostigmine
- D) Flumazenil

Common Traps Students Fall Into

Confusing serotonin syndrome with NMS: Both have fever, rigidity, and altered consciousness. Key difference: clonus + hyperreflexia = serotonin syndrome; lead-pipe rigidity + extrapyramidal signs = NMS. Serotonin syndrome is caused by serotonergic drugs; NMS by dopamine blockers (antipsychotics).
Stating "MAOIs are first-line for depression": They are third-line (or used for atypical depression when others fail), due to food and drug interactions.
Forgetting the 5-week washout for fluoxetine before MAOI: Most students know "2 weeks" but forget fluoxetine needs 5 weeks.
Missing bupropion contraindications: Students name it as a "safe" antidepressant but forget it is contraindicated in seizure disorders and eating disorders.
Confusing clomipramine and clozapine: Clomipramine = TCA (used for OCD); Clozapine = antipsychotic (used for schizophrenia).
Not knowing why TCAs cause arrhythmias in overdose: The mechanism is fast sodium channel blockade (quinidine-like), NOT just anticholinergic effect. QRS widening, not just QT prolongation.
Thinking paroxetine is safe in pregnancy: It is category D; associated with cardiac septal defects in first trimester.
Mirtazapine paradox: Students expect more drowsiness with higher doses - the reverse is true. At low doses: H1 blockade dominates (very sedating). At high doses: NE and 5-HT stimulation counteracts the sedation.

SECTION 8: SPECIAL CLINICAL SITUATIONS

Antidepressants in Pregnancy

Consideration	Recommended Action
First trimester	Sertraline or citalopram considered safest SSRIs
Avoid	Paroxetine (cardiac defects), TCAs
Third trimester concerns	SSRI use → neonatal adaptation syndrome (jitteriness, poor feeding, respiratory distress) in newborn
Breastfeeding	Sertraline has minimal passage into breast milk; generally considered safest
Postpartum depression	Brexanolone (IV, single infusion) or sertraline

Antidepressants in Elderly

Avoid TCAs (falls, confusion, urinary retention, arrhythmias)
Avoid paroxetine (anticholinergic, worst discontinuation)
Prefer sertraline, escitalopram, or citalopram (at lower doses - risk of hyponatremia)
Venlafaxine: monitor blood pressure
Start low, increase slowly ("start low, go slow")
Hyponatremia (SIADH) is a significant risk in elderly on SSRIs

Antidepressants in Cardiac Disease

TCAs: AVOID (arrhythmias, QRS prolongation, orthostatic hypotension)
SSRIs: Sertraline is safest (large randomized controlled trial - SADHART study)
Citalopram/escitalopram: risk of QT prolongation at higher doses
SNRIs (venlafaxine): can raise blood pressure - caution in hypertensives

Antidepressants in Epilepsy

Bupropion: CONTRAINDICATED (lowers seizure threshold)
TCAs: lower seizure threshold (moderate risk)
SSRIs: generally safe; may actually have mild anticonvulsant properties
Safest option: SSRIs (sertraline, escitalopram)

Antidepressants in Hepatic Impairment

Avoid duloxetine (hepatotoxic even in normal function)
Avoid nefazodone (hepatotoxic)
Use SSRIs with caution; reduce dose in severe hepatic impairment
Milnacipran / levomilnacipran: excreted mainly unchanged in urine → safer in liver disease

SECTION 9: HIGH-YIELD REVISION SHEET

╔═══════════════════════════════════════════════════════════════════╗
║         ANTIDEPRESSANTS - ONE PAGE HIGH-YIELD REVISION            ║
╠═══════════════════════════════════════════════════════════════════╣
║ CLASSES & MECHANISMS                                              ║
║ SSRIs      → Block SERT → ↑ Synaptic 5-HT                        ║
║ SNRIs      → Block SERT + NET → ↑ 5-HT + NE                      ║
║ TCAs       → Block SERT + NET + mAChR + H1 + α1 + Na channel     ║
║ MAOIs      → Inhibit MAO → ↑ 5-HT + NE + DA                      ║
║ Mirtazapine → Block α2 + 5-HT2 + H1 → ↑ NE + 5-HT               ║
║ Bupropion  → Block NET + DAT → ↑ NE + DA (no 5-HT effect)        ║
║ Ketamine   → Block NMDA → rapid ↑ BDNF → antidepressant          ║
╠═══════════════════════════════════════════════════════════════════╣
║ ONSET OF ACTION: 2-4 WEEKS for all classical antidepressants      ║
║ WHY: Autoreceptor downregulation + delayed BDNF synthesis          ║
╠═══════════════════════════════════════════════════════════════════╣
║ CRITICAL DRUG INTERACTIONS                                        ║
║ SSRI + MAOI = SEROTONIN SYNDROME (potentially fatal)              ║
║ SSRI + Tramadol = Serotonin Syndrome                              ║
║ MAOI + Tyramine-food = HYPERTENSIVE CRISIS                        ║
║ MAOI + Meperidine = Serotonin Syndrome                            ║
║ Fluoxetine/Paroxetine + TCA = ↑ TCA levels (CYP2D6 inhibition)   ║
╠═══════════════════════════════════════════════════════════════════╣
║ WASHOUT PERIODS BEFORE MAOI                                       ║
║ Fluoxetine → 5 WEEKS (norfluoxetine)                              ║
║ All other SSRIs → 2 weeks                                         ║
║ MAOI → SSRI: also 2 weeks                                         ║
╠═══════════════════════════════════════════════════════════════════╣
║ KEY TOXICITIES                                                    ║
║ TCA overdose → QRS widening → arrhythmia → Rx: IV NaHCO3         ║
║ SSRI → Sexual dysfunction, GI, SIADH, discontinuation syndrome    ║
║ Bupropion → Seizures (contraindicated in eating disorders)        ║
║ Mirtazapine → Sedation + Weight gain + (rare) Agranulocytosis     ║
║ Trazodone → Priapism                                              ║
║ MAOIs → Tyramine reaction, serotonin syndrome                     ║
║ Nefazodone/Duloxetine → Hepatotoxicity                            ║
╠═══════════════════════════════════════════════════════════════════╣
║ DRUGS OF CHOICE                                                   ║
║ Depression (first line) → SSRI (sertraline, escitalopram)         ║
║ Depression + OCD → Fluvoxamine / Clomipramine                     ║
║ Depression + pain → Duloxetine                                    ║
║ Depression + insomnia/low weight → Mirtazapine                    ║
║ Depression + smoking cessation → Bupropion                        ║
║ Atypical depression → MAOIs > TCAs                                ║
║ Postpartum depression → Brexanolone                               ║
║ Treatment-resistant depression → Esketamine + SSRI/SNRI           ║
║ Bulimia nervosa → Fluoxetine (only FDA-approved)                  ║
║ OCD (TCA) → Clomipramine                                          ║
║ Enuresis → Imipramine (low doses)                                 ║
║ Depression in cardiac disease → Sertraline                        ║
╠═══════════════════════════════════════════════════════════════════╣
║ SEROTONIN SYNDROME vs NMS                                         ║
║ Both: Fever, rigidity, altered consciousness                      ║
║ SS: Hyperreflexia, CLONUS, rapid onset, caused by serotonergic Rx ║
║ NMS: Lead-pipe rigidity, bradyreflexia, slow onset, antipsychotics║
╠═══════════════════════════════════════════════════════════════════╣
║ PAROXETINE: avoid pregnancy (FDA Cat D - cardiac defects)         ║
║ CITALOPRAM: QT prolongation at high doses (max 40mg/day)          ║
║ FLUOXETINE: longest half-life, least discontinuation syndrome     ║
╚═══════════════════════════════════════════════════════════════════╝

SECTION 10: SELF-ASSESSMENT

10 Short-Answer Questions with Explanations

Q1: A 35-year-old woman on paroxetine for depression decides to stop her medication abruptly. Within 2 days she develops flu-like symptoms, insomnia, "electric shock" sensations in her hands, and severe dizziness. What is the diagnosis, and which specific feature of paroxetine explains the severity of her symptoms?

Answer: This is antidepressant discontinuation syndrome (also called SSRI discontinuation syndrome or "FINISH" syndrome).

The features described match the FINISH mnemonic: Flu-like symptoms, Insomnia, Nausea/dizziness, Imbalance, Sensory disturbances (electric shocks/"brain zaps"), Hyperarousal.

Paroxetine is the SSRI most associated with severe discontinuation syndrome because:

It has the shortest half-life among the SSRIs (~21 hours)
It has no active long-lived metabolite
It has additional anticholinergic properties that cause a separate withdrawal effect

When abruptly stopped, synaptic serotonin levels fall rapidly - causing a "serotonin withdrawal" state. Fluoxetine has the LEAST discontinuation syndrome because its very long half-life (5-7 weeks when including norfluoxetine) means serotonin levels fall very gradually.

Management: Restart paroxetine and taper gradually (or switch to fluoxetine and taper).

Q2: A medical student reads that antidepressants increase synaptic monoamines within hours of the first dose. His patient asks, "If the drug works immediately on the chemistry, why won't I feel better for 3-4 weeks?" Provide a complete explanation.

Answer: The delay occurs because the antidepressant effect requires multiple sequential biological processes, not just increased monoamine levels:

Autoreceptor feedback (hours to days): When an SSRI blocks SERT, serotonin accumulates. However, presynaptic 5-HT1A autoreceptors detect this excess and fire a "slow down" signal, reducing serotonin synthesis and release. Net serotonin increase is blunted initially.
Autoreceptor desensitization (1-2 weeks): With continued drug exposure, the autoreceptors gradually downregulate (reduce in number and sensitivity). The brake on serotonin release is progressively released.
Postsynaptic receptor adaptation (2-4 weeks): Postsynaptic receptors also undergo downregulation and intracellular signaling changes. The clinical antidepressant effect correlates temporally with these receptor changes - NOT with the acute increase in monoamines.
BDNF synthesis and neuroplasticity (2-4 weeks): The downstream effect of increased monoaminergic activity leads to activation of CREB (cAMP Response Element Binding protein) and increased synthesis of BDNF. BDNF promotes synaptic growth and connectivity (especially in the hippocampus). This process takes weeks, and clinical improvement correlates with it.

This is why the delay is essentially built into the biology of depression treatment - it requires genuine structural and molecular changes in the brain, not just a temporary chemical top-up.

Q3: A 62-year-old man on phenelzine for treatment-resistant depression develops sudden-onset severe headache, palpitations, and blood pressure of 225/135 after eating at an Italian restaurant. What has happened, and what foods might have caused it?

Answer: This is a tyramine hypertensive crisis (the "cheese reaction").

Mechanism: MAO-A in the gut and liver normally metabolizes tyramine absorbed from food. Phenelzine is an irreversible, non-selective MAOI that inhibits both MAO-A and MAO-B. When MAO is inhibited, tyramine escapes first-pass metabolism, reaches the systemic circulation, enters adrenergic nerve terminals, and displaces stored catecholamines (especially norepinephrine), causing a sudden, massive sympathetic surge → hypertensive crisis.

Foods likely responsible at an Italian restaurant:

Aged parmesan cheese (extremely high tyramine)
Salami/pepperoni (cured meats)
Chianti wine (fermented grape)
Olives (pickled/fermented)

Management: IV phentolamine (alpha-blocker) or sodium nitroprusside. Avoid beta-blockers alone (paradoxical hypertension due to unopposed α-receptors).

Q4: Why is sodium bicarbonate used to treat tricyclic antidepressant overdose? What ECG change specifically indicates the need for it?

Answer:

ECG change indicating treatment: Widening of the QRS complex beyond 100ms (particularly >100-120ms). This indicates dangerous sodium channel blockade in the cardiac conduction system.

Why sodium bicarbonate works - three mechanisms:

Alkalinization (pH effect): TCAs are basic drugs with high pKa. At physiologic pH (~7.4), a fraction of the drug is in the unprotonated, lipid-soluble form that can enter and block sodium channels. By raising blood pH to 7.45-7.55 with sodium bicarbonate infusion, more drug becomes protonated (charged) and water-soluble, REDUCING its ability to enter and block the sodium channel. This is a direct pharmacokinetic effect.
Increased protein binding: Alkalinization increases TCA binding to plasma proteins, reducing the free (active) fraction of drug.
Sodium loading: The high sodium content directly competes with TCAs at the sodium channel, helping to "push out" the TCA and restore normal channel function.

Q5: List FIVE antidepressants that do NOT cause significant sexual dysfunction. For each, explain why.

Answer:

Bupropion (NDRI): Acts on norepinephrine and dopamine pathways. Has essentially NO serotonergic activity. Sexual dysfunction from antidepressants is mediated through 5-HT2 receptor stimulation in the CNS and periphery. Without serotonergic effect, sexual dysfunction is rare/absent. Bupropion may even be used to treat SSRI-induced sexual dysfunction.
Mirtazapine (NaSSA): Although it increases serotonin release (via α2 blockade), it simultaneously blocks 5-HT2A and 5-HT2C receptors - the specific serotonin receptor subtypes responsible for sexual dysfunction. The "good" serotonin receptor (5-HT1A) is not blocked.
Trazodone: Primarily a 5-HT2A antagonist. Blocks the receptor responsible for sexual dysfunction. However, causes priapism (in males) due to α1 blockade - which is a DIFFERENT kind of sexual adverse effect.
Agomelatine: Acts on melatonin receptors and 5-HT2C receptors. No effect on serotonin reuptake. Sexual dysfunction is negligible.
Moclobemide (RIMA): Reversible MAO-A inhibitor. Does not have significant 5-HT2 receptor activity. Lower rates of sexual dysfunction than irreversible MAOIs.

Q6: A patient develops fever (41°C), severe muscle rigidity, diaphoresis, confusion, and elevated CK after starting haloperidol for psychosis. Another patient develops similar fever, but with hyperreflexia and clonus after starting sertraline + tramadol. How do you differentiate these two conditions, and how does treatment differ?

Answer:

Feature	Neuroleptic Malignant Syndrome (NMS)	Serotonin Syndrome (SS)
Causative drug	Dopamine blockers (antipsychotics) - haloperidol	Serotonergic drugs - SSRI + tramadol
Onset	Slow (days to weeks)	RAPID (hours)
Neuromuscular	Lead-pipe rigidity, bradyreflexia	Hyperreflexia, CLONUS (rhythmic involuntary contractions)
Other features	Extrapyramidal signs	Mydriasis (dilated pupils)
CK elevation	Very high (severe rhabdomyolysis)	Variable
Mental status	Stupor, obtundation	Agitation, confusion

Treatment:

NMS: Discontinue antipsychotic. Supportive care. Dantrolene (muscle relaxant) and bromocriptine (dopamine agonist) in severe cases.
Serotonin Syndrome: Stop all serotonergic drugs. Benzodiazepines for agitation. Cyproheptadine (5-HT2 antagonist) for moderate-severe cases. Supportive care (cooling, IV fluids). ICU for hyperthermia > 41°C.

Q7: Clomipramine is a tricyclic antidepressant, but it is preferred over other TCAs for OCD. Why?

Answer: Within the TCA class, different drugs have different ratios of SERT:NET inhibition.

Most TCAs inhibit both SERT and NET roughly equally, or are NET-selective (e.g., desipramine).
Clomipramine is unique in having very high affinity for SERT and relatively little affinity for NET. It is the most serotonin-selective TCA.

OCD (Obsessive-Compulsive Disorder) is a condition that specifically responds to serotonergic interventions. It does not respond well to noradrenergic drugs. The serotonin hypothesis of OCD is strong - serotonin pathways in the orbitofrontal cortex - caudate nucleus circuit are implicated.

Because clomipramine is essentially the TCA equivalent of an SSRI (from a 5-HT perspective), it is effective for OCD where other TCAs are not. SSRIs are first-line for OCD; clomipramine is used when SSRIs fail or in severe refractory OCD.

Q8: A 28-year-old man with treatment-resistant depression (failed 3 antidepressant trials) presents to the emergency department with active suicidal ideation. What newer therapeutic option is available, and how does it work differently from classical antidepressants?

Answer: Esketamine (Spravato) - FDA approved (2019) for treatment-resistant depression and MDD with acute suicidal ideation.

How it works differently:

Classical antidepressants work by increasing monoamines (serotonin, norepinephrine, dopamine) at the synapse. This requires 2-4 weeks to produce clinical effect due to the need for downstream receptor adaptation and BDNF synthesis.

Esketamine is the S-enantiomer of ketamine and works as a non-competitive NMDA (N-methyl-D-aspartate) receptor antagonist - targeting the glutamate system, not the monoamine system.

Mechanism: By blocking NMDA receptors, esketamine rapidly activates AMPA receptors, which triggers a fast burst of BDNF synthesis via BDNF-TrkB signaling. This rapidly promotes synaptogenesis (new synaptic connections) in the prefrontal cortex and hippocampus - reversing the synaptic loss that characterizes depression. This entire process occurs within hours to days, not weeks.

How given: Intranasal spray (56mg or 84mg) in a certified healthcare setting. Patient must be monitored for at least 2 hours after each dose due to risk of dissociation, perceptual disturbances, and driving impairment. A REMS program is required.

Q9: A 70-year-old man on sertraline is brought to the emergency department confused, with serum sodium of 122 mEq/L. No other medications. What is the mechanism of this complication, and which patient populations are at highest risk?

Answer: This is SIADH (Syndrome of Inappropriate ADH secretion) induced by sertraline, resulting in hyponatremia.

Mechanism: Serotonin (5-HT) stimulates the release of ADH (antidiuretic hormone / vasopressin) from the posterior pituitary, via 5-HT2C receptor stimulation in the hypothalamus. SSRIs increase serotonergic activity, therefore increase ADH release. Excess ADH causes water retention, diluting the serum → hyponatremia.

Features of SIADH: Hyponatremia + concentrated urine (urine osmolality > serum osmolality) + urine Na > 20 mEq/L + clinically euvolemic.

High-risk populations:

Elderly patients (most common - reduced renal concentrating capacity, lower body water reserve)
Women (hormonal factors)
Patients on diuretics (especially thiazides, which impair diluting ability)
Low body weight
Hot weather / high fluid intake

Management: Stop SSRI, fluid restriction, treat hyponatremia (3% NaCl in severe cases). If SSRI therapy is required, switch to a different antidepressant (e.g., mirtazapine or bupropion, which have lower rates of SIADH) and monitor sodium closely.

Q10: Compare and contrast mirtazapine and bupropion in terms of mechanism, indications, side effects, and which patient profile would benefit most from each.

Answer:

Feature	Mirtazapine	Bupropion
Mechanism	α2-autoreceptor antagonist (removes brake on NE + 5-HT release) + 5-HT2/5-HT3 blocker + potent H1 blocker	Norepinephrine-Dopamine Reuptake Inhibitor (NDRI); also enhances catecholamine release presynaptically
Net effect	↑ NE and 5-HT via disinhibition (not reuptake blockade)	↑ NE and DA (no serotonin effect)
Sedation	HIGH (potent H1 blockade)	LOW to stimulant
Weight	Significant weight GAIN (H1 + 5-HT2C blockade → appetite stimulation)	Weight LOSS or neutral
Sexual dysfunction	RARE (5-HT2 blockade prevents it)	RARE (no serotonin)
Seizure risk	Low	HIGH (dose-dependent)
Anxiety	Reduces anxiety (5-HT3 blockade; sedative)	Can worsen anxiety, insomnia
Main indication	Depression, particularly with insomnia, poor appetite, anxiety, weight loss	Depression particularly with fatigue, weight gain, sexual dysfunction, smoking cessation
Contraindications	Caution: avoid driving initially	Seizure disorder, eating disorders, abrupt alcohol withdrawal
Agranulocytosis	Rare but described (monitor WBC)	Not a concern

Best patient profile for Mirtazapine: An elderly or medically frail depressed patient with significant insomnia, weight loss, poor appetite, and anxiety. The sedating and appetite-stimulating properties are therapeutic in this profile.

Best patient profile for Bupropion: A young or middle-aged depressed patient with fatigue, lethargy, weight gain, sexual dysfunction from prior SSRI, or who wants to quit smoking. The activating effect and lack of sexual side effects are major advantages.

*Sources consulted: Katzung's Basic and Clinical Pharmacology 16th Edition; Stahl's Essential Psychopharmacology; Adams and Victor's Principles of Neurology 12th Edition; Harrison's Principles of Internal Medicine 22nd Edition; Kaplan & Sadock's Comprehensive Textbook of Psychiatry.*Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.

This is a shared conversation. Sign in to Orris to start your own chat.